PGI9 COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF …

P Quon - Value in Health, 2019 - valueinhealthjournal.com
Objectives Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative
colitis (UC). This study assessed the cost-effectiveness of tofacitinib versus available …
被引用次数：1 相关文章

[引用][C] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF …

PL Quon, A Sardesai, S Milev… - ISPOR Europe …, 2019 - ispor.confex.com